Advertisement

Gallopamil (D 600) — a Calcium Antagonist of High Potency and Specificity. Effects on the Myocardium and Pacemakers

  • A. Fleckenstein
  • B. Fleckenstein
  • F. Späh
  • Y. K. Byon
Conference paper

Abstract

It is now accepted that
  1. 1.

    The energy for contraction is obtained from the splitting of adenosine triphosphate (ATP) in the myofibrils.

     
  2. 2.

    Free Ca2+ ions are required to activate the ATP-splitting enzyme (myofibrillar ATPase).

     
  3. 3.

    Physiologically, the contractile force of the myocardial fibres (and the contractile tone of the vascular smooth muscle) can be regulated by variation of Ca2+ influx through the cell membrane into the fibre.

     

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Antoni H, Herkel K, Fleckenstein A (1963) Die Restitution der automatischen Erregungsbildung in Kalium-gelähmten Schrittmacher-Geweben durch Adrenalin — Elektrophysiologische Studien am isolierten Sinusknoten (Meerschweinchen, Rhesusaffe) sowie am Purkinje-Faden (Rhesusaffe). Pflugers Arch 277: 633–649CrossRefGoogle Scholar
  2. 2.
    Antoni H, Oberdisse E (1965) Elektrophysiologische Untersuchungen über die Barium-indu-zierte Schrittmacher-Aktivität im isolierten Säugetiermyokard. Pflugers Arch 284: 259–272CrossRefGoogle Scholar
  3. 3.
    Beck OA, Witt E, Lehmann H-U, Hochrein H (1978) Die Wirkung von Gallopamil (D600) auf die intrakardiale Erregungsleitung und Sinusknotenautomatie beim Menschen. Z Kardiol 67:522–526PubMedGoogle Scholar
  4. 4.
    Bender F (1967) Isoptin zur Behandlung der tachykarden Form des Vorhofflatterns. Med Klin 62:634–636PubMedGoogle Scholar
  5. 5.
    Byon YK, Fleckenstein A (1969) Parallele Beeinflussung von isometrischer Spannungsentwicklung und O2-Verbrauch isolierter Papillarmuskeln unter dem Einfluß von Ca++-Ionen, Adrenalin, Isoproterenol, und organischen Ca++-Antagonisten (Iproveratril, D600, Prenyl-amin). Pflugers Arch 312: R8/9Google Scholar
  6. 6.
    Cranefield PF (1975) The conduction of the cardiac impulse — The slow response and cardiac arrhythmias. Futura, New YorkGoogle Scholar
  7. 7.
    Dargie H, Rowland E, Krikler D (1981) Role of calcium antagonists in cardiovascular therapy. Br Heart J 46: 8–16PubMedCrossRefGoogle Scholar
  8. 8.
    Fleckenstein A (1964) Die Bedeutung der energiereichen Phosphate für Kontraktilität und Tonus des Myokards. Verh Dtsch Ges Inn Med (70th Congr) 81–99Google Scholar
  9. 9.
    Fleckenstein A (1968 a) Experimentelle Pathologie der akuten und chronischen Herzinsuffizienz. Verh Dtsch Ges Herz Kreislaufforsch 34:15–34Google Scholar
  10. 10.
    Fleckenstein A (1968 b) Experimental heart failure due to disturbances in high-energy phosphate metabolism. Proc Vth Eur Congr Cardiol Athens (Sept 1968) 255–269Google Scholar
  11. 11.
    Fleckenstein A (1968 c) Myocardstoffwechsel und Nekrose. In: Heilmeyer L, Holtmeier HJ (Hrsg) VI. Symposium der Deutsch. Ges. für Fortschritte auf dem Gebiet der Inneren Medizin über „Herzinfarkt und Schock“, 8. Nov. 1968 in Freiburg. Thieme, Stuttgart, S 94–109Google Scholar
  12. 12.
    Fleckenstein A (1970) Die Zügelung des Myokardstoffwechsels durch Verapamil. Angriffspunkte und Anwendungsmöglichkeiten. Arzneimittelforsch 20:1317–1322PubMedGoogle Scholar
  13. 13.
    Fleckenstein A (1970/71) Specific inhibitors and promoters of calcium action in the excitation-contraction coupling of heart muscle and their role in the prevention or production of myocardial lesions. In: Harris P, Opie L (eds) Calcium and the Heart, Proceedings of the Meeting of the European Section of the International Study Group for Research in Cardiac Metabolism, London, Sept. 6, 1970. Academic Press, London New York, pp 135–188Google Scholar
  14. 14.
    Fleckenstein A (1977) Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Annu Rev Pharmacol Toxicol 17:149–166PubMedCrossRefGoogle Scholar
  15. 15.
    Fleckenstein A (1978/80) Steuerung der myocardialen Kontraktilität, ATP-Spaltung, Atmungsintensität und Schrittmacher-Funktion durch Calcium-Ionen — Wirkungsmechanismus der Calcium-Antagonisten. In: Fleckenstein A, A Roskamm (Hrsg) Calcium-Antagonismus, Proceed, of an Internat. Symp. 1978 in Frankfurt. Springer, Berlin Heidelberg New York, S1–28Google Scholar
  16. 16.
    Fleckenstein A (1980/81) Pharmacology and electrophysiology of calcium-antagonists. In: Zanchetti A, Krikler DM (eds) Calcium antagonism in cardiovascular therapy: Experience with Verapamil, Internat. Symp. in Florence, 2–4 October 1980. Excerpta Medica, Amsterdam Oxford Princeton, pp 10–29CrossRefGoogle Scholar
  17. 17.
    Fleckenstein A (1983) Calcium-antagonism in heart and smooth muscle — Experimental facts, therapeutic prospects. John Wiley, New YorkGoogle Scholar
  18. 18.
    Fleckenstein A, Döring HJ, Janke J, Byon YK (1975) Basic actions of ions and drugs on myocardial high-energy phosphate metabolism and contractility. In: Schmier J, Eichler O (eds) Handbook of experimental pharmacology, New Series, vol XVI/3. Springer, Berlin Heidelberg New York, pp 345–405Google Scholar
  19. 19.
    Fleckenstein A, Döring JH, Leder O (1969 b) The significance of high-energy phosphate exhaustion in the etiology of isoproterenol-induced cardiac necrosis and its prevention by iprove-ratril, compound D600 or prenylamine. In: Lamarche M, Royer R (eds) International Symposium on Drugs and Metabolism of Myocardium and Striated Muscle, Nancy, pp 11–22Google Scholar
  20. 20.
    Fleckenstein A, Fleckenstein-Grün G (1980) Cardiovascular protection by Ca antagonists. Eur Heart J 1: [Suppl B] 15–21PubMedCrossRefGoogle Scholar
  21. 21.
    Fleckenstein A, Fleckenstein-Grün G, Byon YK (1977) Fundamentale Herz- und Gefäßwirkungen des Ca++-antagonistischen Koronartherapeutikums Fendilin (Sensit)R. Arzneimittelforsch 27: 562–571PubMedGoogle Scholar
  22. 22.
    Fleckenstein A, Fleckenstein-Grün G, Byon YK, Haastert HP, Späh F (1979) Vergleichende Untersuchungen über die Ca++-antagonistischen Grundwirkungen von Niludipin (Bay a 7168) und Nifedipin (Bay a 1040) auf Myokard, Myometrium und glatte Gefäßmuskulatur. Arzneimittelforsch 29: 230–246PubMedGoogle Scholar
  23. 23.
    Fleckenstein A, Grün G, Byon YK, Döring HJ, Tritthart H (1973/75) The basic Ca-an-tagonistic actions of nifedipine on cardiac energy metabolism and vascular smooth muscle tone. In: Hashimoto K, Kimura E, Kobayashi T (eds). New therapy of ischemic heart disease. 1st Internat Adalat Symp. in Tokyo, 1973, University of Tokyo Press, pp 31–44Google Scholar
  24. 24.
    Fleckenstein A, Janke J, Döring JH, Leder O (1971) Die intracelluläre Überladung mit Kalzium als entscheidender Kausalfaktor bei der Entstehung nicht-coronarogener Myokard-Nekrosen. Verh Dtsch Ges Kreislaufforsch 37: 345–353PubMedCrossRefGoogle Scholar
  25. 25.
    Fleckenstein A, Janke J, Döring HJ, Leder O (1974) Myocardial fiber necrosis due to intracellular Ca overload — a new principle in cardiac pathophysiology. In: Dhalla NS (ed) Myocardial biology, recent advances in studies on cardiac structure and metabolism, vol 4. University Park Press, Baltimore London Tokyo, pp 563–580Google Scholar
  26. 26.
    Fleckenstein A, Janke J, Döring HJ, Leder O (1975) Key role of Ca in the production of noncoronarogenic myocardial necroses. In: Fleckenstein A, Rona G (eds) Pathophysiology and morphology of myocardial cell alterations, recent advances in studies on cardiac structure and metabolism vol 6. University Park Press, Baltimore London Tokyo, pp 21–32Google Scholar
  27. 27.
    Fleckenstein A, Janke J, Döring HJ, Pachinger O (1973) Ca overload as the determinant factor in the production of catecholamine-induced myocardial lesions. In: Bajusz E, Rona G (eds) Cardiomyopathies, recent advances in studies on cardiac structure and metabolism, vol 2. University Park Press, Baltimore London Tokyo, pp 455–466Google Scholar
  28. 28.
    Fleckenstein A, Kammermeier H, Döring HJ, Freund HJ (1967) Zum Wirkungsmechanismus neuartiger Koronardilatatoren mit gleichzeitig Sauerstoff-einsparenden Myokard-Effek-ten, Prenylamin und Irpoveratril. Z Kreislaufforsch 56: 716–744, 839–853PubMedGoogle Scholar
  29. 29.
    Fleckenstein A, Späh F (1981/82) Excitation-contraction uncoupling in cardiac muscle. In: Yoshida H, Hagihara Y, Ebashi S (eds) Advances in pharmacology and therapeutics II, vol 3: Cardio-renal and cell pharmacology, Proceed. 8th Internat. Pharmacological Congress, Tokyo, July, 1981. Pergamon, Oxford New York, pp 97–110Google Scholar
  30. 30.
    Fleckenstein A, Tritthart H, Döring HJ, Byon YK (1972) Bay a 1040 — ein hochaktiver Ca++-antagonistischer Inhibitor der elektro-mechanischen Koppelungsprozesse im Warmblü-ter-Myokard. Arzneimittelforsch 22: 22–33PubMedGoogle Scholar
  31. 31.
    Fleckenstein A, Tritthart H, Fleckenstein B, Herbst A, Grün G (1969 a) A new group of competitive Ca-antagonists (Iproveratril, D 600, Prenylamine) with highly potent inhibitory effects on excitationcontraction coupling in mammalian myocardium. Pflugers Arch 307: R25PubMedGoogle Scholar
  32. 32.
    Fleckenstein B (1970) Selektive Zügelung der Myocard-Kontraktilität durch Ca++-antagonistische Hemmstoffe der elektro-mechanischen Koppelung. Med. Dissertation, Universität FreiburgGoogle Scholar
  33. 33.
    Fleckenstein-Grün G, Fleckenstein A, Byon YK, Kim KW (1976/78) Mechanism of action of Ca++-antagonists in the treatment of coronary disease with special reference to perhexiline maleate. Proceed. Symp. on Perhexiline Maleate, Sept. 18, 1976 in Strasbourg. Excerpta Medi-ca, Amsterdam, pp 1–22Google Scholar
  34. 34.
    Garvey HL (1969) The mechanism of action of verapamil on the sinus and AV nodes. Eur J Pharmacol 8:159–166PubMedCrossRefGoogle Scholar
  35. 35.
    Haastert HP, Fleckenstein A (1975) Ca-dependence of supraventricular pacemaker activity and its responsiveness to Ca-antagonistic compounds (verapamil, D 600, nifedipine). Naunyn Schmiedebergs Arch Pharmacol [Suppl] 287: R39PubMedGoogle Scholar
  36. 36.
    Henry PD, Shuchleib R, Borda LJ, Roberts R, Williamson JR, Sobel BE (1978) Effects of nifedipine on myocardial perfusion and ischemic injury in dogs. Circ Res 43: 372–380PubMedCrossRefGoogle Scholar
  37. 37.
    Jasmin G, Bajusz E (1975) Prevention of myocardial degeneration in hamsters with hereditary cardiomyopathy. In: Fleckenstein A, Rona G (eds) Recent advances in studies on cardiac structure and metabolism, vol 6. University Park Press, Baltimore London Tokyo, pp 219–229Google Scholar
  38. 38.
    Jasmin G, Proscheck L (1980) Prevention of myocardial degeneration in hamsters with hereditary cardiomyopathy. Fleckenstein A, Roskamm H (eds) Calcium-Antagonismus. Springer, Berlin Heidelberg New York, pp 144–150CrossRefGoogle Scholar
  39. 39.
    Jasmin G, Solymoss B (1975) Prevention of hereditary cardiomyopathy in the hamster by verapamil and other agents (38771). Proc Soc Exp Biol Med 149:193–198PubMedCrossRefGoogle Scholar
  40. 40.
    Kass RS, Tsien RW (1975) Multiple effects of calcium antagonists on plateau currents in cardiac Purkinje fibres. J Gen Physiol 66:169–192PubMedCrossRefGoogle Scholar
  41. 41.
    Kohlhardt M, Bauer B, Krause H, Fleckenstein A (1972) Differentiation of the transmembrane Na and Ca channel in mammalian cardiac fibres by the use of specific inhibitors. Pflugers Arch 335: 309–322PubMedCrossRefGoogle Scholar
  42. 42.
    Kohlhardt M, Figulla HR, Tripathi O (1976) The slow membrane channel as the predominant mediator of the excitation process of the sinoatrial pacemaker cell. Basic Res Cardiol 71: 17–26PubMedCrossRefGoogle Scholar
  43. 43.
    Krikler DM, Spurrell RAJ (1974) Verapamil in the treatment of paroxysmal supraventricular tachykardia. Postgrad Med 50: 447–453CrossRefGoogle Scholar
  44. 44.
    Landmark K, Amilie JP (1976) A study of the verapamil-induced changes in conductivity and refractoriness and monophasic action potentials of the dog heart in situ. Eur J Cardiol 4: 419–427PubMedGoogle Scholar
  45. 45.
    Lossnitzer K, Janke J, Hein B, Stauch M, Fleckenstein A (1975) Disturbed myocardial calcium metabolism: A possible pathogenetic factor in the hereditary cardiomyopathy of the Syrian hamster. In: Fleckenstein A, Rona G (eds) Recent advances in studies on cardiac structure and metabolism, vol 6. University Park Press, Baltimore London Tokyo, pp 207–217Google Scholar
  46. 46.
    Lossnitzer K, Konrad A, Jakob M (1980) Kardioprotektion durch Kalzium-Antagonisten bei erblich kardiomyopathischen Hamstern. In: Fleckenstein A, Roskamm H (Hrsg) Calcium-Antagonismus. Springer, Berlin Heidelberg New York, S151–171CrossRefGoogle Scholar
  47. 47.
    Lupi GA, Urthaler F, James TN (1979) Effects of verapamil on automaticity and conduction with particular reference to tachyphylaxis. Eur J Cardiol 9: 345–368PubMedGoogle Scholar
  48. 48.
    Mascher D (1970) Electrical and mechanical responses from ventricular muscle fibres after in-activation of the sodium carrying system. Pflugers Arch 317: 359–372PubMedCrossRefGoogle Scholar
  49. 49.
    Mascher D, Peper K (1969) Two components of inward current in myocardial muscle fibers. Pflugers Arch 307:190–203PubMedCrossRefGoogle Scholar
  50. 50.
    McDonald TF, Pelzer D, Trautwein W (1980) On the mechanism of slow calcium channel block in heart. Pflugers Arch 385:175–179PubMedCrossRefGoogle Scholar
  51. 51.
    Melville KI, Shister HE, Huq S (1964) Iproveratril: Experimental data on coronary dilation and antiarrhythmic action. Can Med Assoc J 90: 761–770PubMedGoogle Scholar
  52. 52.
    Nagao T, Matlib MA, Franklin D, Millard RW, Schwartz A (1980) Effects of diltiazem, a calcium antagonist, on regional myocardial function and mitochondria after brief coronary occlusion. J Mol Cell Cardiol 12: 29–43PubMedCrossRefGoogle Scholar
  53. 53.
    Nakajima H, Hoshiyama M, Yamashita K, Kiyomoto A (1975) Effect of diltiazem on electrical and mechanical activity of isolated cardiac ventricular muscle of guinea pig. Jpn J Pharmacol 25: 383–392PubMedCrossRefGoogle Scholar
  54. 54.
    Narimatsua, taira N (1976) Effects on atrio-ventricular conduction of calcium-antagonistic coronary vasodilators, local anaesthetics and quinidine injected into the posterior and the anterior septal artery of the atrio-ventricular node preparation of the dog. Naunyn-Schmiedebergs Arch Pharmacol 294:169–177CrossRefGoogle Scholar
  55. 55.
    Nawrath H, Ten Eick RE, McDonald TF, Trautwein W (1977) On the mechanism underlying the action of D 600 on slow inward current and tension in mammalian myocardium. Circ Res 40: 408–414PubMedCrossRefGoogle Scholar
  56. 56.
    Nayler WG, Grau A, Slade A (1976) A protective effect of verapamil on hypoxic heart muscle. Cardiovasc Res 10: 650–662PubMedCrossRefGoogle Scholar
  57. 57.
    Refsum H (1975) Calcium-antagonistic and anti-arrhythmic effects of nifedipine on the isolated rat atrium. Acta Pharmacol Toxicol 37: 377–386CrossRefGoogle Scholar
  58. 58.
    Refsum H, Landmark K (1975) The effect of a calcium-antagonistic drug, nifedipine, on the mechanical and electrical activity of the isolated rat atrium. Acta Pharmacol Toxicol 37: 369–376CrossRefGoogle Scholar
  59. 59.
    Reuter H, Beeler GW (1969) Calcium current and activation of contraction in ventricular myocardial fibers. Science 162: 399–401CrossRefGoogle Scholar
  60. 60.
    Späh F, Fleckenstein A (1979) Evidence of a new, preferentially Mg-carrying, transport system besides the fast Na and the slow Ca channels in the excited myocardial sarcolemma membrane. J Mol Cell Cardiol 11:1109–1127PubMedCrossRefGoogle Scholar
  61. 61.
    Späh F, Fleckenstein A (1980) Nachweis einer strengen, quantitativen Korrelation zwischen Hemmung des transmembranären Calcium-Influx und der mechanischen Spannungsentwicklung des Myocards unter dem Einfluß verschiedener Calcium-Antagonisten. In: Fleckenstein A, Roskamm H (Hrsg) Calcium-Antagonismus. Springer, Berlin Heidelberg New York, S 29–41CrossRefGoogle Scholar
  62. 62.
    Späh F, Fleckenstein A (1981) The effects of calcium-antagonists, catecholamines, histamine and dibutyryl cyclic AMP on barium-induced ventricular automaticity. Pflugers Arch [Suppl] 389: R8Google Scholar
  63. 63.
    Taira N, Motomura S, Narimatsu A, Iijima T (1975) Experimental pharmacological investigations of effects of nifedipine on atrioventricular conduction in comparison with those of other coronary vasodilators. In: Lochner W, Braasch W, Kroneberg G (eds) New therapy of ischemic heart disease, 2nd Internat. Adalat Symposium. Springer, Berlin Heidelberg New York, pp 40–48Google Scholar
  64. 64.
    Taira N, Narimatsu A (1975) Effects of nifedipine, a potent calcium-antagonistic coronary vasodilator, on atrioventricular conduction and blood flow in the isolated atrioventricular node preparation of the dog. Naunyn Schmiedebergs Arch Pharmacol 290:107–112PubMedCrossRefGoogle Scholar
  65. 65.
    Tritthart H, Fleckenstein B, Fleckenstein A (1970/71) Some fundamental actions of antiarrhythmic drugs on the excitability and the contractility of single myocardial fibres. Proceed. Joint Meeting of the Italian and German Pharmacol. Soc., Heidelberg, 27–30 Sept., 1970, Naunyn Schmiederbergs Arch Pharmacol 269: 212–219CrossRefGoogle Scholar
  66. 66.
    Tritthart H, Volkmann R, Weiss R, Fleckenstein A (1973) Calcium-mediated action potentials in mammalian myocardium. Alteration of membrane response as induced by changes of Cae or by promoters and inhibitors of transmembrane Ca inflow. Naunyn Schmiedebergs Arch Pharmacol 280: 239–252PubMedCrossRefGoogle Scholar
  67. 67.
    Vassort G, Rougier O, Garnier D, Sauviat MP, Coraboeuf E, Gargouil YM (1969) Effects of adrenaline on membrane inward current during the cardiac action potential. Pflugers Arch 309: 70–81PubMedCrossRefGoogle Scholar
  68. 68.
    Wit AL, Cranefield PF (1974) Effect of verapamil on the sinoatrial and atrioventricular nodes of the rabbit and the mechanism by which it arrests reentrant atrioventricular nodal tachycardia. Circ Res 35: 413–425PubMedCrossRefGoogle Scholar
  69. 69.
    Zipes DP, Fischer JC (1974) Effects of agents which inhibit the slow channel on sinus node automaticity and atrioventricular conduction in the dog. Circ Res 34:184–192PubMedCrossRefGoogle Scholar
  70. 70.
    Zipes DP, Mendez C (1973) Action of manganese and tetrodotoxin on atrioventricular nodal transmembrane potentials in isolated rabbit hearts. Circ Res 32:447–454PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1984

Authors and Affiliations

  • A. Fleckenstein
  • B. Fleckenstein
  • F. Späh
  • Y. K. Byon

There are no affiliations available

Personalised recommendations